Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Macular degeneration Stories

2013-11-04 23:27:31

“For many, bright light is a simple, cost-effective intervention to recover lost visual function,” said Jasper Ridge President, Dr. Peter Borden. Researchers recommend the use of high illumination such as VisionEdge™ in low vision exams and rehabilitation programs. San Mateo, CA (PRWEB) November 04, 2013 The VisionEdge™ Diagnostic Kit (VE-100DK) makes it easy to incorporate controlled high illumination in low vision exams. The small, bright, portable instrument is key to quick...

2013-10-31 23:29:18

ResearchMoz include new market research report "Asia-Pacific Macular Degeneration Therapeutics Market to 2019: Industry Analysis, Size, Share, Growth, Trends And Forecast" to its huge collection of research reports. Click Here For Download Detail Report - http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html Albany, NY (PRWEB) October 31, 2013 Macular...

2013-10-31 16:26:43

New Formulas Designed for Patient Types Studied in the AREDS 2 Clinical Research Study ST. LOUIS, Oct. 31, 2013 /PRNewswire/ -- ZeaVision®, the parent company of EyePromise eye vitamins, introduces two new AREDS 2 formulas, EyePromise AREDS 2 Plus Zinc-Free and EyePromise AREDS 2 Plus with a Multi-Vitamin. Recent research indicates that some may achieve better vision protection by taking an eye vitamin that does not contain zinc, thus the reason EyePromise brings a science-based,...

2013-10-30 23:27:54

RnRMarketResearch.com adds Latest Report on “Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 – Existing Angiogenics Retain Dominance Though High Unmet Need Remains” to its store. Dallas, TX (PRWEB) October 30, 2013 This report provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms;...

2013-10-30 23:26:30

Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, reports on a recent study revealing a new topical treatment to treat vision loss caused by macular generation. Toronto, ON (PRWEB) October 30, 2013 Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, reports on a recent study revealing a new topical treatment to treat vision loss caused by macular generation. As Bel Marra Health reports in...

2013-10-29 20:22:35

PARSIPPANY, N.J., Oct. 29, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with Opthea Pty Ltd of Melbourne, Australia. The contract covers process development and cGMP manufacture by DSM for Opthea's lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel...

2013-10-28 23:27:41

Vision Without Glasses reviews have been flooding the Internet and HealthAvenger.com reveals the truth about this program that claims to restore poor vision without the need for surgery, let alone wearing glasses or lenses. Houston, TX (PRWEB) October 28, 2013 Duke Peterson’s claims that Vision Without Glasses is a natural and non-invasive means to naturally improve one’s sight without expense, pain or risk has caught the attention of HealthAvenger.com’s Stan Stevenson, prompting an...

2013-10-24 23:00:12

The article on the site Healthreviewcenter.com provides people with 6 revolutionary tips that guide people on how to get better eyesight quickly. Seattle, Wa (PRWEB) October 24, 2013 The article includes two parts, offering six explosive tips on how to get better eyesight that are really effective for people. It was written especially for people who want to improve eyesight and avoid common eye diseases without using lenses, drugs, or surgery. In the first section, the article shows that...

2013-10-22 20:21:33

LEUVEN, Belgium, October 23, 2013 /PRNewswire/ -- Final guidance confirms metamorphopsia, an early symptom of VMT, as severe and distressing, requiring early treatment - NICE final guidance recommends reimbursement of JETREA for treatment of a broad range of VMT patients, from early stage to late-stage: patients with epiretinal membranes (ERMs) are excluded - NICE recommends reimbursement for...

2013-10-21 08:28:31

TARRYTOWN, N.Y., Oct. 21, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results for EYLEA(®) (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). In this trial, 53% of patients who received EYLEA 2 milligram (mg) every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of...